By Colin Kellaher
Seelos Therapeutics shares tumbled in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a Phase 2 study of its SLS-002 depression drug candidate missed its key goal due to an shortfall in enrollment.
The New York company said SLS-002 showed clinically meaningful treatment effects across multiple…
Read the full article here